What is Trevi Therapeutics, Inc.'s non-cash lease expense?

Trevi Therapeutics, Inc. (TRVI) reported non-cash lease expense of $105K in Q1 2026.

How has Trevi Therapeutics, Inc.'s non-cash lease expense changed year-over-year?

Trevi Therapeutics, Inc.'s non-cash lease expense decreased by 6.3% year-over-year, from $112K to $105K.

Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.

Indivior Pharmaceuticals, Inc. INDV

$2M0.0%

Operating income-$14.9M-30.0%

Net income-$13.2M-27.6%

EPS (diluted)-$0.090.0%

Cash & equivalents$19.4M+0.2%

Total debt$682.0K-28.7%

Total equity$172.1M+73.1%

Total assets$179.6M+67.8%

Operating cash flow-$16.7M-23.8%

CapEx$102.0K—

Free cash flow-$16.8M—

Market cap$2.47B+152%

Enterprise value$2.45B+157%

Return on equity-33.6%-9.4pp

Debt / equity0×0.0×

Current ratio24.8×+9.4×

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Trevi Therapeutics, Inc.'s non-cash lease expense?: Trevi Therapeutics, Inc. (TRVI) reported non-cash lease expense of $105K in Q1 2026.
How has Trevi Therapeutics, Inc.'s non-cash lease expense changed year-over-year?: Trevi Therapeutics, Inc.'s non-cash lease expense decreased by 6.3% year-over-year, from $112K to $105K.
What does non-cash lease expense mean?: Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.